Eli Lilly and Company

(New York Stock Exchange)
Back to all articles
Bullish +65

Eli Lilly’s (LLY) Growth Story Keeps Adding Chapters

AI-generated analysis

πŸ“ˆ Eli Lilly reported a 48% year-over-year revenue increase in Q2, with adjusted EPS reaching $8.38.

πŸ‡¬πŸ‡§ The UK MHRA approved Foundayo, an oral GLP-1, making it the first European market to greenlight the pill.

🌍 Foundayo is currently under regulatory review in over 40 additional countries with a global rollout expected by 2027.

πŸ’Š Foundayo offers a distinct advantage over Novo Nordisk's oral Wegovy as it does not require patients to fast for 30 minutes before ingestion.

πŸ“ˆ Management raised full-year revenue guidance to a range of $85 billion to $87 billion.

πŸ‘₯ More than 80% of Foundayo prescriptions were issued to patients who had never previously taken a GLP-1 drug.

πŸ’° Average realized prices across the GLP-1 portfolio fell 13% year-over-year due to strategic price cuts to widen access.

πŸ“Š Volume for the GLP-1 portfolio increased by 60% over the same period, offsetting the decline in average prices.

⚠️ Mounjaro and Zepbound combined accounted for 65% of second-quarter revenue, highlighting portfolio concentration risk.

πŸ“‰ LLY trades at 32.47 times forward earnings, significantly higher than the 18.5x average for healthcare stocks.

βš”οΈ Competition is intensifying with Novo Nordisk's CagriSema approaching and semaglutide patents expiring in India, China, and Brazil.

πŸ“‰ Hedge fund ownership of Eli Lilly decreased from 137 funds to 132 in the most recent quarter.

Bullish Signals
  • LLY achieved a 48% year-over-year revenue growth in Q2, demonstrating strong commercial performance.
  • The UK regulatory approval for Foundayo expands the company's geographic footprint and product accessibility.
  • Management raised full-year revenue guidance to $85-$87 billion, signaling confidence in future demand.
  • Foundayo captures a new segment of needle-averse patients without cannibalizing existing injectable sales.
  • The company successfully expanded its market by securing over 80% of Foundayo prescriptions from first-time GLP-1 users.
  • Volume growth of 60% effectively offset the 13% decline in average realized prices, maintaining revenue momentum.
Risk Factors
  • LLY trades at a premium valuation of 32.47x forward earnings compared to the 18.5x sector average.
  • The portfolio is heavily concentrated with Mounjaro and Zepbound representing 65% of Q2 revenue.
  • Average realized prices fell 13% year-over-year due to price cuts intended to improve patient access.
  • Patent expirations for semaglutide in India, China, and Brazil open the door for generic competition.
  • Hedge fund ownership slipped from 137 to 132 funds, indicating some institutional caution.
Full Analysis
Eli Lilly (LLY) reported a robust second quarter with revenue surging 48% year-over-year, driven primarily by its GLP-1 weight loss portfolio. The company received a significant regulatory milestone on August 10 when the UK's Medicines and Healthcare products Regulatory Agency approved Foundayo, an oral GLP-1 for weight management and type 2 diabetes. This approval made Britain the first European market to greenlight the pill, causing LLY stock to rise nearly 4%. The company is now under regulatory review in over 40 additional countries, with a global rollout expected across major markets by 2027. Lilly is strategically diversifying its treatment portfolio beyond injectables like Zepbound by adding oral options and developing retatrutide for patients requiring deeper weight loss or managing complications like sleep apnea. Management highlighted that more than 80% of Foundayo prescriptions went to patients who had never taken a GLP-1 before, indicating market expansion rather than cannibalization of existing sales. Consequently, the company raised its full-year revenue guidance to between $85 billion and $87 billion, reflecting strong demand and successful access programs like the new Medicare initiative. Despite the growth, the article notes significant valuation concerns and competitive headwinds. LLY trades at 32.47 times forward earnings, well above the healthcare sector average of 18.5x, assuming continued compounding growth without stumbles. The portfolio remains concentrated with Mounjaro and Zepbound accounting for 65% of second-quarter revenue. Additionally, average realized prices across the GLP-1 portfolio fell 13% year-over-year due to price cuts aimed at widening access, though volume increased by 60%. Competition is intensifying as Novo Nordisk's CagriSema approaches and patent protections for semaglutide expire in key markets like India, China, and Brazil. The article concludes that while LLY has successfully transformed a single drug into a multi-product platform with expanding regulatory reach, the high valuation leaves little cushion against potential volume erosion from rivals or generic competition. Hedge fund ownership saw a modest decline to 132 funds, yet short interest remains low at 1.02% of the float. The core investment thesis rests on whether the company can maintain its growth trajectory despite these concentration risks and pricing pressures.